08:00 | Registration |
|
Session: Challenges and Opportunities |
| |
09:00 |  | Keynote Presentation Technologies for Theranostics
Tony Cass, Professor of Chemical Biology, Imperial College London, United Kingdom
The idea of basing a therapeutic regimen on the genotype/phenotype of a patient requires both advanced diagnostic and drug delivery technologies in addition to an informatics linkage. In my presentation I will describe some of the component approaches to achieving this as well as the challenges in their implementation. |
|
09:30 | Developing Theranostics for Personalised Medicine of Infection: Opportunities, Roadblocks and Solutions
Herman Goossens, Professor, University of Antwerp, Belgium
Theranostics provide great opportunities to identify the pathogen and the correct drug to be given. The technology is changing rapidly, but most of these new technologies have not yet found applications in clinical diagnostics. Therefore, we need new initiatives that bring together a multidisciplinary team of researchers aligned towards the goal of developing successful theranostics. |
10:00 | The Novel Theranostic Biosensing System for the Evaluation of Therapeutic Molecules Toward the Amyloid-Forming Neurodegenerative Disease Causative Proteins
Koji Sode, Chair, Tokyo University of Agriculture and Technology, Japan
I report the novel biomonitoring system for the amyloid forming protein cytotoxicity evaluation, which is being utilized for both diagnosis of the sample toxicity and therapeutic reagent evaluation. As a model of amyloid forming protein, the evaluation of the cytotoxicity of various a-synuclein variants, the causative protein of Parkinson’s disease, is being introduced. |
10:30 | Coffee Break and Networking in Main Exhibition Hall |
|
Session: Towards Real-Time Clinical Measurement |
| |
11:15 | Microfluidic and Transducer Technologies for Lab on a Chip Applications
Daniel Hill, Project Coordinator, Universitat De Valencia, Spain
Recent developments of Lab on Chip technologies are presented with a special emphasis on those based on photonics sensors. In introducing the European Projects where they have taken place we show how they could be used to personalize medicine. |
11:45 | Standardised Microsystem Platforms for Proteomic and Genomic Analysis for Screening of Specific Diseases
Ciara Sullivan, Research Professor, University Rovira I Virgili, Spain
Integrated microsystems for detection of autoantibodies and HLA typing with a common footprint and electromechanical interface with a lightweight instrument with embedded communication abilities for direct transfer of test result to the electronic patient record on a health information system are presented. |
12:15 | Lunch and Networking in Main Exhibition Hall |
13:30 | Poster Presentations |
14:15 | Integration of Nucleic Acid, Protein and Small Molecule Detection on a Rapid, Point-of-Care Multi-Parameter Platform
Edward Blair, Executive Chair, Integrated Magnetics Systems Limited, United Kingdom
A demonstrator of the Scottish Enterprise Biosensor Platform (BSP) can run protein and nucleic acid diagnostics in parallel in about 10 minutes. Key to this is the integration of sample preparation, analyte process and signal detection modules through novel microfluidics. |
15:15 | Coffee Break and Networking in Main Exhibition Hall |
|
Session: Developing Personalised Therapies |
| |
16:00 | Magnetic Polymersomes for Theranostics in Cancer
Sebastien Lecommandoux, Professor, Universite de Bordeaux, France
The controlled release of doxorubicin by radio-frequency magnetic hyperthermia from multifunctional magnetic polymersomes is demonstrated, showing the viability of the concept of magneto-chemotherapy in cancer. This research is developed in the framework of a FP7 European project named “Nanother”. |
16:30 | The Role of POCT in Theranostics; Innovation from Philips
Jeroen Nieuwenhuis, Technology Director, Philips Healthcare Incubator, Switzerland
Improving therapy compliance offers an opportunity to increase drug efficacy and improve treatment outcomes. Point-of-care immunoassays can play a key role in making this happen. An open diagnostic platform strategy will be discussed to enable a win-win for pharma and patient. |
17:00 | Biomarkers in Early Development
Hans Winkler, Senior Director and Global Head, Johnson & Johnson, Belgium
In early development, two types of biomarkers are important:
- Pharmacodynamic markers to assess compound activity in humans (phase I) and to provide quantitative data supporting Phase II transition and dose selection.
- Predictive markers to assess identification of patient populations that receive a high level of clinical benefit. For these, the development of robust assays early on is critical. |
17:30 | Close of Day One |
